Modality
ADC
MOA
CD47i
Target
IL-23
Pathway
Angiogenesis
MDD
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Mar 2031
Phase 1Current
NCT04422799
1,240 pts·MDD
2018-08→2031-03·Completed
NCT07169758
908 pts·MDD
2019-11→TBD·Active
2,148 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-104.9y awayPh2 Data· MDD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2031-03-10 · 4.9y away
MDD
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04422799 | Phase 1/2 | MDD | Completed | 1240 | PANSS |
| NCT07169758 | Phase 1/2 | MDD | Active | 908 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |